From August 11th to 13th, 2020, Co-founders of Bridge Point Capital, Nadia Tian and Mark Young were invited to the Canaccord Genuity 40th Annual Growth Conference. For three highly productive days, some of the best global growth universe came together virtually to share knowledge, discuss emerging trends, build relationships, identify opportunities, and ignite global ideas for growth. Now in its 40th year, the Annual Growth Conference has become one of the industry's premier investment industry conferences for companies and investors focused on growth.
Due to COVID-19, this year’s conference switched to virtual for the first time with over 500 growth public/private companies and private equity and venture capital investors attending. Among the participants, 1/3 are growth firms or investors in the healthcare sector. As a recession-proof industry, healthcare has outperformed many other sectors during the pandemic and ignited investment enthusiasm.
To maximize participants’ online engagement, the conference was composed of company showcases, speaker panels and one-on-one meetings. It not only provided growth firms and investors an opportunity to connect, but also offered a platform where attendees can learn from industry leaders and discuss the latest trends.
Our Chief Science Officer Yan Meng attended one-on-one meetings with a viriaty of uprising start-ups in the healthcare space, and had further discussions with two of the most eye-catching companies — Cardiva and Akoya Biosciences.
Cardiva is a developer of vascular closure technology intended to help the body heal itself following catheterization procedures. Akoya Biosciences is a developer of a multiparametric fluorescence imaging technology designed to study tissue organization.
Through these conversations, we hope to discover and support healthcare and life science companies that possess revolutionary technologies to promote human health.
Bridge Point Capital is a private equity firm based in New York with a focus on U.S.-China cross-border investment. We invest in disruptive late-stage healthcare companies that can benefit from penetrating the vast yet unexplored Chinese healthcare market. We aim to leverage our expertise in both healthcare and capital markets to establish a sustainable investment platform for our investors.